IBA receives FDA approval for its proton therapy specific Cone Beam CT (CBCT) system and announces strategic alliance with Philips
IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer recently announced that it had received combined clearances from the U.S. Food and Drug Administration (FDA) that will enable IBA to market-launch the proton therapy specific Cone Beam Computed Tomography (CBCT) system. IBA has received clearance from the FDA for its imaging platform adaPT Insight* (FDA 510(k) K132847) and for the Compact Gantry Beam Line (FDA 510(k) K132919). Those combined clearances will enable the CBCT to be marketed in IBA’s two Proton Therapy versions, Proteus®PLUS and Proteus®ONE, in 2014 and 2015 respectively.
As a component of IBA’s Image Guided Proton Therapy (IGPT) system, CBCT provides 3D imaging for increased accuracy in patient treatment. It is fully integrated with IBA’s imaging platform adaPT Insight to offer fast 6D corrections of patient positioning for the Proteus®PLUS and Proteus®ONE proton therapy systems. IBA’s first CBCT is at the validation phase and the first clinical use is expected for the second half of 2014.
Olivier Legrain, Chief Executive Officer of IBA commented: “We are delighted to be the first company to receive marketing authorization from the FDA for the proton therapy specific CBCT technology. The development of imaging capabilities is critical to the expansion of the use of proton therapy in new cancer indications and IBA has developed advanced radiation therapy solutions that improve the overall treatment experience for both clinicians and patients. CBCT is just one example of the latest technological advancements achieved by IBA as we maintain our unrivalled position as the world’s leader in the innovation and delivery of proton therapy.”
On September 11 IBA announced the signing of a global collaboration with Philips Healthcare. The collaboration covers sales, marketing, research and development (R&D) of imaging and therapy solutions in oncology. By merging their respective expertise in therapy and image guidance systems, IBA and Philips will innovate with an integrated vision for more efficient, personalized cancer care. Leveraging high quality imaging and proton therapy offers the potential to increase confidence in the diagnosis and treatment of cancer, reduce short- and long-term side-effects and potentially enhance the quality of life of the patient before, during and after treatment, while reducing the cost of treatment for the healthcare system. The collaboration will also enable both organizations to mutually leverage technologies and solutions: IBA will benefit from Philips diagnostic imaging products offered to oncology care centres, while Philips will leverage IBA proton therapy solutions within its offering for customers in select markets around the world. The commercial collaboration also includes an integrated offering for Molecular Imaging Centres, combining IBA’s expertise in PET radioisotope production centres with Philips’ imaging and diagnostics expertise.
www.iba-worldwide.com
